<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>BiG生物创新社 | wechat-feeds</title><link>http://MzkxNTA5NjM1OA.favicon.privacyhide.com/favicon.ico</link><description>BiG，Biologics Innovation Group是由致力于从事生物医药领域研究、开发、应用、临床、投资等工作的独立个人，自愿组织的一个专业/非盈利性机构。正式成立于2014年，迄今会员490余人，相继举办20余场行业峰会。</description><managingEditor> (hellodword)</managingEditor><pubDate>Wed, 03 Mar 2021 17:17:55 +0800</pubDate><image><url>http://MzkxNTA5NjM1OA.favicon.privacyhide.com/favicon.ico</url><title>BiG生物创新社 | wechat-feeds</title><link>http://MzkxNTA5NjM1OA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>免疫单药真的落寞了么，双抗市场究竟蓝海多大？</title><link>https://mp.weixin.qq.com/s/HUjzyzoM77IcpUomM9LIZA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/m6gqgND1GwQeibj9MjkPorTwxJmx3iaSw0kesBvsDPRezd0SMX8wybs1MvmddyRrvWgTqytXQcRnYbFp9b1ibTjdw/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>一文梳理双抗格局]]></content:encoded><pubDate>Wed, 03 Mar 2021 17:04:13 +0800</pubDate></item><item><title>缺氧耐药新解法！贝伐珠单抗难治性GBM 2期达到主要终点</title><link>https://mp.weixin.qq.com/s/lWm4o7yj24kobzPJksNxSQ</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/m6gqgND1GwS1HXkebqgt82f0b4ZTy9ylFjEqibf7ZzFr5HXVneINSZxk3oMZmhJWL7IicwdbzMN5kACKmaOOduVQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>有潜力的胶质母细胞瘤新药]]></content:encoded><pubDate>Mon, 01 Mar 2021 17:12:48 +0800</pubDate></item><item><title>信达生物新冠抗体项目美国FDA IND获批，苏桥助力2000L GMP生产</title><link>https://mp.weixin.qq.com/s/xTCYtnj4N4VgnqPafbGZYA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/m6gqgND1GwS1HXkebqgt82f0b4ZTy9yljicI2Oa5epKiaUwxbj5h1iaNyEOSian7PhuLrKYkk7IAz9nuLlB02NO0gg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>]]></content:encoded><pubDate>Mon, 01 Mar 2021 17:12:48 +0800</pubDate></item><item><title>百花齐放！常见双特异性抗体技术平台</title><link>https://mp.weixin.qq.com/s/nPIdl0-0FASlqh_LYXoAhA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/m6gqgND1GwQbo0fBJiaPHrNYhTBxFXEXvHR7VH7ia0tjdbGFO8C1tb2qsPmaR2uibcjTCK8cDaBzxhTwTPUEAcdXQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>双抗目前有超过200种format]]></content:encoded><pubDate>Sat, 27 Feb 2021 22:22:03 +0800</pubDate></item><item><title>4-1BB+T细胞：免疫治疗革命的主角</title><link>https://mp.weixin.qq.com/s/D4pDhkRvytBPW3rH0NFBhw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/m6gqgND1GwQtylGWANJwicfOPm3KqJTicILicvIiaynuRzfLwNibGnQiaC6JUFjaBLfNqSeanSUInqrH9RKOWWvY0S7g/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>4-1BB的潜力]]></content:encoded><pubDate>Fri, 26 Feb 2021 17:56:16 +0800</pubDate></item><item><title>新江湖｜医普科诺加入BiG会员机构！</title><link>https://mp.weixin.qq.com/s/mFMUuGfa3Xmx5TbjLtmHMw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/m6gqgND1GwQtylGWANJwicfOPm3KqJTicImibHVzrPrmY9FkMvXfhLRCYPK5DKSdbTKtzBCgKlM6jTFGOkGxJjmjg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>Scientific Driven, Making Impact.]]></content:encoded><pubDate>Fri, 26 Feb 2021 17:56:16 +0800</pubDate></item><item><title>双特异性纳米抗体，激活1型NKT细胞</title><link>https://mp.weixin.qq.com/s/vYG2X0q93FPymhsDu0aIeQ</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/m6gqgND1GwT1loQIFAUhfGSNWY9oSOhBYKAl13FVQiaWibc24xxiaFK9diajD1vo0ibuicEfTeEQADNEzTP2tlWJtUug/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>NKT细胞越来越受关注。]]></content:encoded><pubDate>Tue, 23 Feb 2021 15:17:59 +0800</pubDate></item><item><title>抗Galectin-9与GITR激动剂的协同抗肿瘤作用</title><link>https://mp.weixin.qq.com/s/9sntacAt2lvp0GOAotOmwg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/m6gqgND1GwT1loQIFAUhfGSNWY9oSOhBQcyrGYZD7ialYBtdybDmpmhiaUpX0Jd8N1pibXkXXGiaLXBzUXJt6expog/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>Gal-9，一个非常有希望的免疫治疗靶点]]></content:encoded><pubDate>Mon, 22 Feb 2021 17:03:52 +0800</pubDate></item><item><title>以IL-2/IL-2R经典传奇，开启新的十年！</title><link>https://mp.weixin.qq.com/s/MqPAUzIITKSY-5sHh2lJBQ</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/m6gqgND1GwTXMcLXygk9Yu8z68bCeHQGPJv3BORlsVTyzsv8hfu7qrhPeiayKu2ic1ae0SA44GS9bZOurmPaqTQA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>研究简史及药物开发]]></content:encoded><pubDate>Thu, 18 Feb 2021 16:55:42 +0800</pubDate></item><item><title>低毒有效！“睡美人” CAR-T I/II期临床试验结果</title><link>https://mp.weixin.qq.com/s/otcr9WCq5mRU0O7I-U8kUQ</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/m6gqgND1GwTXMcLXygk9Yu8z68bCeHQGfbxmox6eNs5u6vVLuqoZyHrYiaS2ZXwhjtTfXErgBwve56Mj2STkO6A/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>有望提高免疫细胞治疗可及性吗？]]></content:encoded><pubDate>Thu, 18 Feb 2021 16:50:27 +0800</pubDate></item><item><title>LILRB4，癌症和自身免疫疾病新秀靶点</title><link>https://mp.weixin.qq.com/s/rO8ZQbg24r3f5nwtM_uvlA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/m6gqgND1GwRAqmvQicwE7nLl6BsLqYibHhlQm0BAXtM94Ilbng2U5jeiaPMLp6TcjfSjibSYe1hDnBegZibJ2jXEfXg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>一种新的治疗策略]]></content:encoded><pubDate>Mon, 15 Feb 2021 08:20:03 +0800</pubDate></item><item><title>全面开花！B7-H3的抗体靶向治疗</title><link>https://mp.weixin.qq.com/s/IcYAS6rfZYl6DKKWM68tyg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/m6gqgND1GwS6DZvFFkicyiag9utmwsDDcfYKVU2QQas5eXgTzSf9HHEvNJHGLt51hIxXc8jWXqRPSdHroT9YtYEQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>一个非常有吸引力的靶点]]></content:encoded><pubDate>Fri, 12 Feb 2021 22:59:04 +0800</pubDate></item></channel></rss>